Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis.
A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjogren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab.